There is much interest in manipulating PGC‐1α (which is upregulated by the glitazone drugs) as a way of inhibiting renal fibrosis in human kidney diseases (diabetic and non‐diabetic; see Clark & Parikh, 2021). The gene discussed is PPARGC1A; the disease is kidney disorder.